<DOC>
	<DOCNO>NCT02551172</DOCNO>
	<brief_summary>To investigate efficacy safety administration HCP1105 hyperlipidemic patient high risk CHD .</brief_summary>
	<brief_title>Evaluating Efficacy Safety HCP1105 Combined Hyperlipidemic Patients With High Risk CHD</brief_title>
	<detailed_description>An efficacy safety study HCP1105 Capsule combine hyperlipidemic patient high risk Coronary Heart Disease ( CHD ) : A randomized , double-blind , multicenter , phase 3 study .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>age 19â‰¤ Subjects ability comprehend objective , content study property study drug participate trial willingness sign inform consent write History clinically significant hypersensitivity reaction HMGCoA reductase inhibitor Omega3 Subject active liver disease severe liver failure ( Continuous elevation AST , ALT level unspecified cause AST , ALT level exceeds three time maximum upper range . )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>